Loading...
XTAI
1795
Market cap1.96bUSD
May 07, Last price  
225.00TWD
1D
-0.66%
1Q
-17.88%
Jan 2017
275.63%
Name

Lotus Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
11.79
P/S
3.21
EPS
19.09
Div Yield, %
2.07%
Shrs. gr., 5y
1.69%
Rev. gr., 5y
15.16%
Revenues
18.58b
+9.59%
606,822,000590,184,000532,209,000503,153,000658,481,0002,310,021,0005,521,937,0005,902,566,0006,423,760,0006,428,894,0009,174,740,00010,728,583,00012,649,189,00014,632,772,00016,957,971,00018,584,227,000
Net income
5.07b
+23.38%
3,117,00015,051,000-38,403,000-193,234,00011,882,000-442,127,000103,949,000-134,041,0007,685,00099,476,000662,807,0001,026,796,0001,403,371,0003,020,757,0004,105,626,0005,065,510,000
CFO
6.15b
+281.29%
89,499,00059,194,000-76,294,000-54,453,000-95,837,000-1,032,408,0001,077,573,0001,233,001,000592,293,000796,978,000302,809,0001,948,682,000119,662,0003,719,418,0001,614,207,0006,154,866,000
Dividend
Aug 05, 20244.64745 TWD/sh
Earnings
May 09, 2025

Profile

Lotus Pharmaceutical Co., Ltd. research, develops, manufactures, and sells generic pharmaceutical products in Taiwan, Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system disease. The company also sells and markets a portfolio of over-the-counter medicines. In addition, it engages in wholesale of cosmetics; retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. Further, the company offers pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan. Lotus Pharmaceutical Co., Ltd. is a subsidiary of Alvogen Emerging Markets Holdings Limited.
URL
https://www.lotuspharm.com.tw/
IPO date
Dec 13, 2004
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
18,584,227
9.59%
16,957,971
15.89%
14,632,772
15.68%
Cost of revenue
12,567,209
12,059,066
10,524,992
Unusual Expense (Income)
NOPBT
6,017,018
4,898,905
4,107,780
NOPBT Margin
32.38%
28.89%
28.07%
Operating Taxes
1,294,068
997,299
919,455
Tax Rate
21.51%
20.36%
22.38%
NOPAT
4,722,950
3,901,606
3,188,325
Net income
5,065,510
23.38%
4,105,626
35.91%
3,020,757
115.25%
Dividends
(1,231,688)
(906,227)
(506,058)
Dividend yield
1.74%
1.27%
0.79%
Proceeds from repurchase of equity
259
598
BB yield
0.00%
0.00%
Debt
Debt current
5,088,913
1,883,203
274,859
Long-term debt
8,855,969
9,954,026
8,748,919
Deferred revenue
26,563
45,326
65,915
Other long-term liabilities
785,690
665,566
607,744
Net debt
7,914,769
7,018,037
4,871,159
Cash flow
Cash from operating activities
6,154,866
1,614,207
3,719,418
CAPEX
(353,838)
(410,568)
(3,069,391)
Cash from investing activities
(2,690,718)
(3,249,290)
(4,656,148)
Cash from financing activities
714,089
1,402,672
1,261,731
FCF
3,861,884
(2,079,309)
3,701,418
Balance
Cash
6,030,113
1,770,880
1,983,383
Long term investments
3,048,312
2,169,236
Excess cash
5,100,902
3,971,293
3,420,980
Stockholders' equity
15,318,689
10,254,183
7,736,885
Invested Capital
30,558,281
25,658,023
19,307,386
ROIC
16.80%
17.35%
17.70%
ROCE
16.37%
16.14%
17.72%
EV
Common stock shares outstanding
263,044
262,024
261,684
Price
269.50
-0.92%
272.00
10.57%
246.00
152.31%
Market cap
70,890,322
-0.53%
71,270,528
10.71%
64,374,264
157.22%
EV
78,805,091
78,288,565
69,245,423
EBITDA
7,300,271
6,109,544
5,044,646
EV/EBITDA
10.79
12.81
13.73
Interest
570,765
557,397
382,460
Interest/NOPBT
9.49%
11.38%
9.31%